Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Apr.29

News

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

2025.Apr.23

News

OBI-822 Completes Second Interim Analysis of Phase III Trial
OBI Announces Trial Termination, Refocuses Resources on ADC Development

2025.Apr.23

News

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs),
GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science.

Read More

2025.Apr.23

Announcement

To announce the press release for material information in a press conference

2025.Apr.23

Announcement

OBI decided to terminate OBI-822 Phase 3 study based on DSMB's recommendation and to redirect resources towards ADCs development

2025.Apr.22

Announcement

Announcement on behalf of OBIGEN of Establishment of the Remuneration Committee and Appointment of the First-Term Members

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 Investors' Meeting - Innovation and Optimism

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact